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Abstract
Background: Drug‐induced liver injury (DILI) and idiopathic autoimmune hepatitis 
(AIH) are competing diagnoses in patients with acute liver injury (ALI) and drug in‐
take. In absence of unequivocal markers, scores like RUCAM and AIH are used to 
distinguish both entities. However, in some cases the diagnosis remains ambiguous. 
Our aim was to identify a simple parameter to discriminate DILI and AIH shortly after 
starting corticosteroid treatment.
Methods: For the current analysis, 44 patients with ALI who took at least one drug 
and who received corticosteroids were included and comprised 22 DILI and 22 AIH 
cases. Scores of AIH and RUCAM were calculated at initial presentation, the final di‐
agnosis was made from analysing the course of disease. Changes in the serum alanine 
aminotransferase (ALT) concentrations after starting corticosteroid treatment were 
determined and compared between the DILI and AIH groups.
Results: Fifty‐nine per cent of patients (n = 26) were correctly classified at presenta‐
tion by AIH score and RUCAM respectively. However, in one‐third (n = 13) of the 44 
patients, results were inconclusive and five other patients were misclassified. The 
decrease in ALT levels 1 week after the initiation of steroid therapy was significantly 
more pronounced in patients with the final diagnosis of DILI than in AIH patients 
(accuracy 77%). This difference was also observed in the 18 initially misclassified or 
inconclusive cases (accuracy 83%).
Conclusion: Short‐term response of ALT to corticosteroid therapy helps to differenti‐
ate DILI and AIH. This finding may be helpful in treatment decision for patients with 
inconclusive diagnostic scores.
K E Y W O R D S
acute liver injury, alanine aminotransferase, DILI, medication, toxicity
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1  | INTRODUC TION
Drug‐induced liver injury (DILI) is a rare adverse drug reaction that is 
the leading cause of acute liver failure (ALF) in the US and Europe.1‐4 
The reported incidence ranges from 14 to 19 cases per 100 000 
individuals per year, but might be higher since only a few popula‐
tion‐based studies exist.5,6 Currently, DILI is a diagnosis of exclu‐
sion; other, more common causes of liver injury must be ruled out to 
establish the diagnosis. In absence of a reliable laboratory test, DILI 
diagnosis can be a challenge, particularly when features of autoim‐
mune hepatitis (AIH) are present.7 Since immunologic mechanisms 
play a major role in pathogenesis of idiosyncratic DILI8 a range of 
drugs has been associated with injury patterns that may be indistin‐
guishable from idiopathic AIH.9‐11
Moreover, histological patterns typically associated with AIH 
have also been observed in patients with DILI, further complicat‐
ing the differentiation between the two entities.12‐14 The finding of 
cirrhosis at presentation and subsequent signs of chronicity favour 
the diagnosis of AIH. Yet, since only 20%‐30% of patients with acute 
liver injury (ALI) due to AIH will show signs of cirrhosis,11,15,16 the 
absence of cirrhotic liver tissue cannot be used as a diagnostic cri‐
terion for DILI.
At initial presentation, autoimmune features cannot reliably dis‐
criminate between DILI and aggravated pre‐existing or new‐onset 
AIH.11,17 In these unclear cases, international treatment guidelines 
recommend treatment with corticosteroids and close monitoring 
of the patients upon reduction in immunosuppressive therapy.18‐20 
Although some patients with DILI and autoimmune features will re‐
cover spontaneously upon discontinuation of the causative agent, 
immunosuppressive drugs are often used if liver injury persists.17 DILI 
with autoimmune features usually responds well to corticosteroid 
therapy and the tapering and ultimate withdrawal of immunosuppres‐
sive therapy is rarely accompanied by a relapse.11,17,21 In contrast, most 
patients suffering from AIH present with a flare up of hepatitis when 
immunosuppressive therapy is reduced or withdrawn after remission, 
and in most cases, patients require long‐term, possibly lifelong im‐
munosuppression.22,23 Therefore, once corticosteroid treatment has 
been initiated in DILI patients – either because of the suspicion of AIH 
or because of persistent liver injury despite withdrawal of medica‐
tion – the exclusion of AIH can only reliably be confirmed by a more 
favourable outcome under long‐term immunosuppression. Taking into 
the account the more beneficial response towards corticosteroids 
seen in DILI patients, it seems plausible that discontinuation could be 
conducted more rapidly in those patients and therefore unnecessary 
long‐term immunosuppression with a broad spectrum of side effects 
might be avoided. However, data about the early response towards 
immunosuppressive therapy in DILI and AIH patients are scarce. 
Without being able to reliably differentiate DILI and AIH, rapid reduc‐
tion or discontinuation of immunosuppressive therapy harbours the 
potentially life‐threatening risk of disease recurrence in the case the 
underlying cause of liver injury was idiopathic AIH.
Therefore, in the specific subset of patients with an inconclusive 
diagnosis, reliable diagnostic criteria are needed to differentiate DILI 
and AIH early in the disease course to provide the optimal therapy 
for each individual patient.
Considering the above‐mentioned different features DILI and 
AIH during long‐term immunosuppression, we hypothesized that 
the early response towards corticosteroid treatment might be more 
marked in patients with DILI than in AIH patients. To this end, we 
investigated 44 patients (22 patients with DILI and 22 patients with 
AIH as final diagnosis) from our prospective study on idiosyncratic 
DILI.24 They either presented with autoimmune features and/or did 
not show any improvement of liver injury despite the withdrawal 
of the causative agent and thus received corticosteroids during the 
course of the disease. We aimed to identify a simple parameter such 
as ALT for the differentiation of DILI and AIH early after treatment 
initiation and compared the diagnostic value of AIH score, RUCAM, 
histology and outcome during short‐term immunosuppression.
2  | METHODS
2.1 | Patients
Data from patients who were referred to the University Hospital 
Munich and recruited for our study on the diagnosis of idiosyncratic 
DILI in patients with ALI (ClinicalTrials.gov: NCT 02353455) were 
analysed. For this investigation, all patients presenting at our centre 
between March 2013 and October 2018 with ALI and the intake of 
at least one drug or herbal and dietary supplement were evaluated. 
Written informed consent was obtained from each patient. The study 
protocol conforms to the ethical guidelines of the Declaration of 
Helsinki and was approved by the ethics committee of the Faculty of 
Medicine, LMU Munich (Project Number 55‐13). All authors had access 
to the study data and reviewed and approved the final manuscript.
At enrolment, all study participants were questioned about 
their medical history, symptoms associated with liver injury, co‐
morbidities, current or previous medications and the consumption 
of herbal and dietary supplements or over‐the‐counter medica‐
tion. Age, gender, ethnicity, height, weight and relevant data from 
clinical investigations were recorded. Serological data on hepatitis 
A, B, C, D and E, cytomegalovirus, Epstein‐Barr virus and herpes 
simplex virus were available from all patients enrolled. Indirect 
immunofluorescence testing for antinuclear antibodies (ANA) and 
anti‐mitochondrial antibodies (AMA) is regarded positive by the 
standards of our hospital's Institute for Laboratory Medicine at 
Key points
• This study shows that the decrease in alanine ami‐
notransferase serum concentrations after 1 week of 
corticosteroid treatment helps to separate drug‐induced 
liver injury (DILI) from autoimmune hepatitis patients.
• This may prevent unnecessary long‐term treatment with 
immunosuppressive drugs in DILI patients.
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titre was ≥1:100. Titres for smooth muscle antibodies (SMA), solu‐
ble liver antigen (SLA) and liver kidney microsome (LKM) obtained 
by ELISA and/or Western Blot are not available and only positive 
or negative results being reported. Immunoglobulin G (IgG) lev‐
els with a normal range of 7‐16 g/L were tested in every patient 
upon onset. Genotyping of human leukocyte antigen (HLA)‐DR1 
locus was additionally performed in a proportion of patients using 
the Genotyping Kits OneLambda RSSO1A 015_02, OneLambda 
RSSOH1C 06A_02, OneLambda RSSO1B 018_04 20012016, 
OneLambda RSSOH2B1 011_0 and OneLambda RSSO2Q 011_04 
161018. Histology reports from patients in whom liver biopsy was 
performed as deemed necessary by the treating physicians were 
extracted from the medical records. The type of infiltration (portal 
vs interface) and of cholestasis (ductal, canalicular, hepatocellular 
or hepatocellular and canalicular) as well as the degree of fibrosis 
(mild, moderate, intermediate and severe) were recorded. The in‐
tensity of the infiltrates, cholestasis and specific inflammatory cell 
infiltrates was graded as mild, intermediate and severe. In addition, 
the diagnosis suggested in the final histology report was noted.
For the current analysis, out of 288 patients enrolled in our 
study until October 2018, 44 patients fulfilling the criteria for ALI 
(see next paragraph) who received corticosteroids during the course 
of their disease were analysed. The final diagnosis was DILI in 22 
cases and AIH in 22 cases. Of the 116 patients with non‐DILI–re‐
lated ALI, 86 patients were excluded from the analysis because of 
alternative causes of ALI, leaving 30 AIH cases. Eight of those AIH 
patients were excluded because they were either lost to follow‐up 
or follow‐up was too short to verify the final diagnosis. In addition, 
150 DILI patients were excluded because they did not receive cor‐
ticosteroids (Figure 1). The final diagnosis of DILI or AIH was made 
retrospectively after reassessment of the initially suspected diagno‐
sis based on the course of disease, response to steroid treatment and 
relapse after withdrawal of immunosuppression and liver histology 
(Figure 2). In addition, the MetaHeps test, using monocyte‐derived 
hepatocyte‐like (MH) cells to detect drug toxicity with high sensitiv‐
ity and specificity,25 was performed for every patient.
Acute liver injury was defined according to consensus criteria 
established by an expert group in 2011: (a) alanine aminotransferase 
activity (ALT) ≥ 5 × upper limit of normal (ULN); (b) alkaline phospha‐
tase activity (ALP) ≥ 2 × ULN or (c) ALT ≥ 3 × ULN and total biliru‐
bin (TB) ≥ 2 × ULN.26‐29 The ULN was 35 U/L (women) and 50 U/L 
(men) for ALT. For ALP, the ULN 105/135 U/L (women/men) and the 
ULN for TB was 1 mg/dL. The Roussel Uclaf Causality Assessment 
Method (RUCAM) was calculated for up to five drugs and the maxi‐
mum score was used for diagnosis.30 The causative agent was iden‐
tified using the RUCAM and expert opinion and supported by the 
MH cell test results. For every patient, the pretreatment AIH score 
defined by the Revised Scoring System for the diagnosis of AIH was 
calculated.31 The cut‐off values for probable and definite AIH were 
12 and 15 respectively.
Acute liver failure was defined by the criteria of the American 
Association for the Study of Liver Diseases: (a) the absence of pre‐
existing liver disease; (b) coagulopathy with an INR (international 
normalized ratio) ≥1.5 in the absence of oral anticoagulants; and (c) 
hepatic encephalopathy.28
All patients were closely monitored after the initiation of corti‐
costeroid treatments, including an evaluation of the clinical devel‐
opment and laboratory tests to assess liver damage and function. 
The maximum reduction in ALT concentrations per day during week 
1 and 2 was assessed for every patient. Maximum reduction in ALT 
was calculated using ALT values on day 5‐7 for week 1 and day 11‐14 
for week 2. In order to avoid bias by different days of blood sampling 
after treatment initiation, ΔALT per day was calculated from the dif‐
ference of ALT at treatment initiation and ALT on day X of treatment 
divided by X. ΔALT% per day was calculated as percentage of ΔALT 
per day of ALT at treatment initiation to minimize bias by different 
ALT levels at treatment initiation. Relapse was defined as an increase 
in ALT levels that exceeded the ULN or baseline value in case ALT 
levels had not previously been normalized. Although relapse of AIH 
is defined as an elevation of the ALT level >3 × ULN according to cri‐
teria established by the international AIH group, a relapse might also 
occur with a more moderate increase in ALT levels, particularly when 
IgG levels are also elevated again.18 Thus, patients who presented 
with an increase in ALT levels ranging between 1 and 3 times the 
ULN or baseline value after tapering or withdrawal of immunosup‐
pressive therapy were also regarded as having a relapse and treat‐
ment was reinitiated accordingly.
2.2 | Statistical analysis
Data were tested for normal distribution using the Kolmogorov‐
Smirnov test and are presented as mean ± SD or median and range 
respectively. Statistical analyses were performed using SPSS soft‐
ware (version 25.0.0.1; IBM). After testing for a normal distribution, 
parametric or non‐parametric tests (Chi‐square test, Fisher's exact 
test, Student's t test, Kruskal‐Wallis test or Mann‐Whitney U test) 
were applied. P < .05 was considered to indicate a statically sig‐
nificant difference. Receiver operating characteristic (ROC) curves 
were calculated using SPSS to evaluate the cut‐off values, sensitivity 
and specificity of the investigated parameters.
3  | RESULTS
3.1 | Characteristics of the patients at presentation
3.1.1 | General features
Fourty‐four patients were included in this study, 22 with DILI and 22 
with AIH as final diagnosis. Patient characteristics are summarized in 
Table 1. No significant differences were observed in age, gender distri‐
bution, ethnicity or body mass index. The distribution of the severity 
score and the incidence of ALF were also comparable in both groups. 
Analysis of HLA genes was performed in 16 patients (10 DILI and 6 
AIH patients, respectively) with similar rates of HLA‐DRB1*03 or HLA‐
DRB1*04 polymorphisms in DILI and AIH patients (70.0% and 66.7% 
respectively; P = .639). The causative agents of DILI episodes were 
     |  1909WEBER Et al.
non‐steroidal anti‐inflammatory drugs (NSAIDs) in six cases (meta‐
mizole in three and diclofenac in three cases), lipid‐lowering agents 
in two cases (atorvastatin/ezetimibe and atorvastatin respectively), 
new oral anticoagulants in two cases (rivaroxaban and dabigatran), 
an herbal medication in one case (celandine) and other drugs in eight 
cases (amitriptyline, imatinib, infliximab, interferon beta, methocarba‐
mol, methylprednisolone, minocycline and pembrolizumab). In three 
cases, two different drugs were equally possible causative agents 
(metamizole or umckaloabo, simvastatin or carbimazole and diclofenac 
or medroxyprogesterone, respectively). For a detailed listing of all 
drugs taken by DILI patients please refer to Table S1. For the concomi‐
tant medication of the individual AIH patients refer to Table S2.
3.2 | Comparison of RUCAM and AIH scores
The median RUCAM of patients with DILI as final diagnosis was 6 
(3‐10) (median, range), and thus was significantly higher than the 
score of the patients with AIH (P < .01), who presented with a median 
F I G U R E  1   For the current retrospective analysis, patients were selected from the study on the diagnosis of idiosyncratic DILI in patients 
with acute liver injury: 22 DILI patients who received corticosteroids and 22 AIH patients. Number and reasons of primary exclusion as 
well as exclusion from the current analysis are demonstrated. Percentages of secondary exclusion were calculated from the baseline of 
288 patients included in the study. AIH, autoimmune hepatitis; ALI, acute liver failure; CMV, cardiomegaly virus; DIKI, drug‐induced kidney 
injury; DILI, drug‐induced liver injury; EBV, Epstein‐Barr‐Virus; HAV, hepatitis A virus, HEV, hepatitis E virus; HHV 6, human herpesvirus 
6; NASH, non‐alcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; SSC, secondary sclerosing 
cholangitis. Metabolic disorders included Wilson's disease and hemochromatosis, other non‐viral infections included liver abscesses and 
echinococcosis
Patients with ALI screened 
for the study
n = 327
Non-DILI ALI
n = 116 (35.5%)
DILI
n = 172 (52.3%)
AIH
n = 30 (10.5%)
Other causes
n = 86 (30.0%)
Cholangitis/Cholelithiasis: n = 15 (5.2%)
HEV: n = 12 (4.2%)
Alcohol: n = 10 (3.5%)
Cardiac failure: n = 8 (2.8%)
SSC: n = 6 (2.1%)
NASH: n = 5 (1.7%)
Other autoimmune diseases: n = 5 (1.7%)
Metabolic disorders: n = 4 (1.4%)
PBC: n = 4 (1.4%)
PSC: n = 3 (1.1%)
Other non-viral infections: n = 3 (1.1%) 
HAV: n = 2 (0.7%)
HHV 6: n = 2 (0.7%)
EBV: n = 2 (0.7%)
CMV: n = 1 (0.4%)
Malignant infiltration: n = 1 (0.4%)
Inconclusive/others: n = 3 (1.1%)
DILI with steroids
included in analysis
n = 22 (7.7%)
AIH with steroids 
included in analysis
n = 22 (7.7%)
AIH excluded
n = 8 (2.8%)
Lost to follow-up n=8
Primarily excluded from the 
study
n = 39 (12.2 %)
• Healthy: n = 16 (4.9%)
• Age < 18 years: n = 7 (2.1%)
• No consent: n = 3 (0.9%)
• DIKI: n = 2 (0.6%)
• Other reasons: n = 10 (3.1%)
Patients with ALI included 
in the study 
n = 288 (87.8%)
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score of 3.5 (0‐7). The sensitivity of the RUCAM with a cut‐off of 6 
was 32% and the specificity was 91%.
The AIH score was significantly higher in patients with AIH as 
final diagnosis than in patients with DILI, who presented median 
scores of 13 (9‐18) and 9.5 (4‐14) respectively (P = .01). The sensi‐
tivity of the pretreatment AIH score with a cut‐off of ≥12 in our co‐
hort was 59% and the specificity was 82%. When the simplified AIH 
score32 was calculated, no statistical difference was found between 
DILI and AIH patients with a median of 4 (2‐6) in DILI vs 5 (1‐7) in AIH 
patients respectively (P = .385).
Antinuclear antibodies and elevated IgG serum levels are con‐
sidered as markers pointing towards the diagnosis of AIH.31,32 
Interestingly, the rate of patients tested positive for ANA did not 
differ significantly between DILI and AIH (AIH: 86.4% positive, 
DILI 77.3% positive). In some patients, other antibodies related to 
autoimmune liver diseases were detected as well with the most 
prevalent being extractable nuclear antigens (ENA) and AMA in 
the AIH group (n = 3 for ENA and AMA respectively, 13.6%) and 
SMA (n = 3, 13.6%) and AMA‐M2 (n = 2, 9.1%) in the DILI group. 
For an overview of all autoantibodies found in DILI and AIH pa‐
tients, please also refer to Tables S1 and S2. Elevated IgG lev‐
els were more common in AIH patients (59.1% vs 36.4% in AIH 
and DILI patients respectively), however this difference was not 
statistically significant (P = .087). Diagnostic performance was 
similar to the AIH score, encompassing both IgG and ANA (data 
not shown).
3.3 | Establishing the final diagnosis
3.3.1 | RUCAM and AIH scores
According to the pretreatment AIH scores and RUCAM, 18 pa‐
tients were initially diagnosed with AIH and 13 with DILI as they 
presented with an AIH score ≥12 and a RUCAM <6 or an AIH score 
<12 and a RUCAM ≥6 respectively. However, the RUCAM and AIH 
scores were misleading in five of those 31 patients: three patients 
who were initially thought to suffer from AIH were finally diag‐
nosed with DILI, while two patients who were initially thought to 
have DILI were diagnosed with AIH during the follow‐up period 
(Figure 2). Furthermore, RUCAM and AIH scores were inconclusive 
in 13 cases (30%) with both scores either suggesting DILI and AIH 
as the probable diagnosis or both score pointing towards DILI and 
AIH being unlikely: In four DILI patients and one AIH patient, AIH 
score was ≥12 and RUCAM score was ≥6, while in five DILI and 
three AIH patients, AIH score was <12 and RUCAM score was <6. 
For those patients, the final diagnosis could only be established in 
F I G U R E  2   The RUCAM and AIH scores were conclusive in 31 cases, however five of those were misdiagnosed by the scoring 
systems. Thus, 10 DILI and 16 AIH patients were correctly diagnosed by AIH score and RUCAM. In 13 cases, AIH score and RUCAM were 
inconclusive: five patients had an AIH score ≥12 and RUCAM <6; eight patients had an AIH score <12 and RUCAM <6. AIH, autoimmune‐
hepatitis; DILI, drug‐induced liver injury; RUCAM, Roussel Uclaf Causality Assessment Method
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the further course of the disease considering the response towards 
immunosuppressive treatment.
3.3.2 | Histological patterns
Histology was available for all 22 AIH patients and 15 of the 22 DILI 
patients. There were no significant differences regarding the intensity 
of inflammatory infiltrates or cholestasis, the type of the predominant 
inflammatory cells or the grade of fibrosis (Figure 3). The only discrimi‐
nating feature in our cohort was the finding of an interface infiltrate, 
which was significantly more frequent in AIH patients (20 AIH vs 8 DILI 
patients, P = .01). In addition, a tendency towards a stronger eosino‐
phile infiltrate was observed in AIH patients (P = .113). In the majority 
of AIH cases (n = 16/22; 72.7%) the histological pattern was compat‐
ible with AIH, while in 73.3% of the DILI patients (n = 11/15) histologi‐
cal features were pointing towards a possible or probable diagnosis of 
DILI. Yet, in five AIH patients (22.7%) and three DILI patients (20.0%), 
the diagnosis of DILI and AIH was equally likely according to the his‐
tological features (Tables S3 and S4). The sensitivity and specificity of 
the histology regarding diagnosis of DILI therefore were 73%.
Patient characteristics DILI (n = 22) AIH (n = 22) P‐value
Age, years 50 (22‐76) 53 (22‐76) .60
Female sex, n (%) 14 (63.6%) 14 (63.6%) .62
Ethnicity: Caucasian, n (%) 22 (100%) 22 (100%) na
BMI, kg/m2a 24.2 (16.8‐42.5) 24.2 (19.2‐34.6) .87
RUCAM score max., pointsa 6 (3‐10) 3.5 (0‐7) <.001b
≥6 points, n (%) 14 (63.6%) 3 (13.6%)
AIH score, pointsa 9.5 (4‐14) 13 (9‐18) .001b
≥12 points, n (%) 7 (31.8%) 17 (77.3%)
Revised AIH score, pointsa 4 (2‐6) 5 (1‐7) .39
Latency, da 81 (12‐1589) 40.5 (0‐1470) .03b
Time interval until the initiation 
of corticosteroids, d
19.5 (7‐195) 16 (7‐88) .39
ANA titrea 1:300 (0‐1:25 600) 1:400 (0‐1:12 800) .33
ANA positive, n (%) 17 (77.3%) 19 (86.4%) .43
IgG serum levels, g/La 11.0 (7.5‐26.9) 17.3 (6.6‐31.7) .09
IgG > 16 g/L, n (%) 8 (36.4%) 13 (59.1%) .13
HLA‐DRB3 or 4, n of all (%) 7/10 (70.0%) 4/6 (66.7%) .64
ALT at onset, (× ULN)a 27.1 (3.3‐66.7) 27.8 (13.4‐58.8) .94
ALT at treatment initiation 
(× ULN)a
28.9 (6.7‐88.3) 25.1 (4.3‐46.7) .20
R ratio at onseta 16.6 (2.9‐36.7) 18 (2.8‐59.2) .73
R ratio PTBLa 15.8 (1.8‐74.7) 16.4 (2.9‐47.4) .71
Pattern of liver injury at onset    
Hepatocellular 21 (95.5%) 20 (90.9%) .55
Mixed 1 (4.5%) 2 (9.1%)  
ALF, n (%) 8 (36.4%) 6 (27.3%) .52
Severity scorea 2 (1‐5) 2 (1‐5) .68
Corticosteroid of choice   .31
Prednisolone, n (%) 21 (95.5%) 22 (100%)  
Methylprednisolone, n (%) 1 (4.5 5) 0  
Maximum dosage of corticoster‐
oid, shown as hydrocortisone 
dose equivalent, mga
240 (160‐5000) 240 (160‐400) .12
Abbreviations: AIH, autoimmune hepatitis; ALF, acute liver failure; ALT, alanine aminotransferase; 
ANA, anti‐nuclear antibodies; BMI, body mass index; DILI, drug‐induced liver injury: PTBL, peak 
total bilirubin level; RUCAM, Roussel Uclaf Causality Assessment Method; RUCAM max, highest 
RUCAM in the given patient, if several drugs were involved; ULN, upper limit of normal.
aMedians and lower and upper limits are shown. 
*Statistically significant difference (P < .05). 
TA B L E  1   Patient characteristics of 
AIH‐patients and DILI‐patients
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3.3.3 | MH cell test
The MH cell test, which was performed in every patient included 
in this study, showed negative results for all AIH patients (n = 22, 
100%) but identified one causative drug in 18 (81.8%) and two pos‐
sible causatives drugs in four (18.2%) patients with DILI as the final 
diagnosis (Table S3).
3.4 | Corticosteroid treatment
3.4.1 | Indication for immunosuppression
The majority of patients with the final diagnosis of DILI pre‐
sented with autoimmune features (18 of 22; 81.8%), including 
elevated autoantibody titres and IgG concentrations or an AIH 
score of 12 or higher, initially suggesting that AIH was a prob‐
able diagnosis.
Overall, ALT concentrations tended to be higher in the DILI 
group at the time of initiation of treatment when compared to the 
AIH patients, although this difference did not reach statistical sig‐
nificance (Figure 4).
The indication for the initiation of treatment with corticoste‐
roids in 17 of the 18 DILI patients with autoimmune features was 
persistent or progressive ALT elevation despite the withdrawal 
of the causative drug in 12 cases and development of ALF with 
coagulopathy in five cases. One patient had developed liver in‐
jury because of a programmed cell death protein 1 (PD‐1) inhib‐
itor, a drug known to cause immune‐mediated liver injury that 
responds well to corticosteroids33 and thus received immuno‐
suppressive therapy.
Regarding the four patients without autoimmune features, one 
patient suffered from ALI because of minocycline, which has been 
described to cause DILI with autoimmune features resembling AIH 
that responds well to corticosteroid treatment11,34 and immuno‐
suppressive treatment was initiated as a result of persistently el‐
evated ALT levels. The remaining three patients presented with 
persistency of ALT elevation in spite of the discontinuation of the 
suspected drug and thus with seronegative AIH being a possible 
diagnosis received immunosuppression at the judgement of the 
treating physician.
All patients with AIH (n = 22; 100%) and most of the patients 
with DILI (n = 21; 95.5%) received prednisolone. One patient 
with DILI had clinical signs of concomitant relapsing‐remitting 
multiple sclerosis, and thus was treated with methylpredniso‐
lone with the initial steroid dose determined based on the MS 
relapse (5000 mg). The median maximum equivalent cortisol 
dosage was 240 mg for both patients with DILI and AIH, with 
a range of 160‐5000 mg and 160‐400 mg respectively (Table 1 
and Tables S1 and S2).
3.4.2 | ALT concentrations early after starting 
corticosteroid treatment
Notably, significant differences in the absolute and relative reduc‐
tions in ALT levels per day during the first week of corticosteroid 
treatment were observed between the patients with DILI or AIH as 
final diagnosis: 3.5 × ULN per day (0.2‐7.8) for patients with DILI vs 
1.9 × ULN per day (0‐5.7; P = .02) for patients with AIH or in relative 
terms, 10.8% (1.7%‐20.0%) per day for patients with DILI vs 7.5% per 
day (0%‐12.5%; P < .01) for patients with AIH.
The sensitivity and specificity of the relative reduction in ALT 
levels per day were 77% respectively, using 9% decrease per day 
during the first week as cut‐off value. Thus, a 9% or greater re‐
duction in ALT levels per day after the initiation of steroid ther‐
apy suggested a diagnosis of DILI and showed a higher sensitivity 
than the RUCAM and pretreatment AIH score with only a mildly 
reduced specificity.
During week 2, there was also a tendency towards a higher max‐
imum reduction in ALT per day, although this difference was non‐
significant: 1.8 × ULN (0.1‐5.0) or 6.6% (1.4%‐9.1%) per day in DILI 
patients vs 1.4 × ULN (0.1‐23.3) or 5.7% (2.1%‐10.9%) per day in AIH 
patients (P = .367 and .350 respectively).
F I G U R E  3   The graph shows the mean 
ALT serum concentrations × ULN along 
with the standard deviation (SD) measured 
at the time of initiation of corticosteroid 
treatment and the minimal ALT reached 
in treatment week 1 in patients with 
AIH (black line) and DILI (grey line). AIH, 
autoimmune‐hepatitis; ALT, alanine 
aminotransferase; DILI, drug‐induced liver 
injury
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3.4.3 | Subgroup analysis of unequivocal cases and 
complex patients
In order to evaluate ALT decrease in patients unequivocally identi‐
fied by the diagnostic scores, we performed a ROC analysis of these 
24 cases (eight DILI, 16 AIH). The relative reduction in ALT during 
the first week showed best differentiation of DILI and AIH at 9% of 
pretreatment ALT per day with a sensitivity for DILI of 88% and a 
specificity of 75% respectively.
We also performed a subgroup analysis of the patients initially 
misclassified (n = 5) by AIH and RUCAM score or with an inconclu‐
sive initial diagnosis because of the AIH score and RUCAM (n = 13). 
Of the patients studied, five cases had an AIH score ≥12 and 
RUCAM ≥6 suggesting both AIH and DILI as probable diagnosis. 
On the other hand, AIH score <12 and RUCAM <6 was found in 
eight cases, indicating that both AIH and DILI were equally un‐
likely to have caused ALI despite a high clinical suspicion and rule‐
out of alternative diagnosis. Thus, a total of 18 patients (41%) were 
either misclassified (n = 5) or inconclusive (n = 13) at initial presen‐
tation. Strikingly, the relative reduction in ALT per day in the first 
week with a cut‐off of ≥9% for the diagnosis of DILI differentiated 
DILI and AIH in every misclassified patient. Moreover, the relative 
reduction in ALT per day in the first week also accurately distin‐
guished between AIH and DILI in three of four the AIH and seven 
of the nine DILI patients with an inconclusive initial diagnosis, 
reaching a sensitivity of 78% and specificity of 75% for the diagno‐
sis of DILI. In the combined group of five misclassified patients and 
13 patients with inconclusive initial scores (n = 18), relative ALT 
F I G U R E  4   Percentage was given as number of patients with the specific features relative to the total number of samples available. 
Statistical significance is indicated by * (P < .05). AIH, autoimmune hepatitis; DILI, drug‐induced liver injury
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reduction could differentiate AIH and DILI in 15 cases resulting in 
a sensitivity and specificity of 83%. Histological reports pointed 
towards the right diagnosis in only 11 of those 16 cases (sensitivity 
60%, specificity 83%), while in two of those cases histology was 
not available. Thus, in patients with an inconclusive diagnosis upon 
presentation, the relative reduction in ALT shortly after initiation 
of steroid treatment was more accurate in distinguishing AIH and 
DILI than a liver biopsy. For an overview of the individual patients' 
diagnosis according to AIH score and RUCAM, histological report 
and ALT reduction under immunosuppression please also refer to 
Tables S3 and S4.
3.5 | Long‐term follow‐up
3.5.1 | Normalization of ALT levels
All patients from our study cohort were regularly seen in our liver 
unit with clinical and laboratory follow‐up assessments. The median 
follow‐up period was 19 months (3‐54) for patients with DILI and 
23 months (1‐220) for patients with AIH respectively. During long‐
term follow‐up, four patients had a fatal outcome or needed liver 
transplantation: One patient who had developed DILI as a result of 
anti‐PD‐1 antibody treatment with pembrolizumab for metastatic 
melanoma died from cancer‐related causes approximately 3 months 
after inclusion in our study. One DILI and two AIH patients under‐
went high urgency liver transplantation due to progressive liver fail‐
ure. After exclusion of those four patients, the minimal follow‐up in 
AIH patients was 7 and 10 months in the DILI group.
The rates of remission under immunosuppression, defined as 
normalization of ALT serum levels, tended to be higher in the DILI 
group compared to the AIH group (95.5% vs 77.3%; P = .08). The 
median duration until serum ALT concentrations normalized was 
86 days (range 14‐264 days) and 84 days (range 14‐362 days) for 
patients with DILI and AIH respectively (P = .82).
3.5.2 | Relapse after tapering or discontinuation of 
immunosuppressive therapy
The above‐mentioned four patients with a fatal outcome or the 
need for liver transplantation were excluded from the final analysis 
leaving 20 DILI and 20 AIH for a final follow‐up. The outcome of 
those remaining patients varied strongly between the two groups: 
Additional immunosuppression with azathioprine or mycophenolic 
acid during tapering of corticosteroids was significantly less frequent 
in DILI patients: 17 (85.0%) AIH patients received azathioprine or 
mycophenolic acid, while in the DILI group only four (20.0%) patients 
did (two patients with relapse and two patients who were initiated 
on azathioprine because of initial AIH diagnosis; P < .01 [17 von 20 
vs 4 von 20]). Furthermore, immunosuppression could successfully 
be discontinued completely in 17 of the 20 (85.0%) DILI patients, but 
only in one of the 20 AIH patients (5.0%; P < .01). The proportion of 
patients showing a relapse during the long‐term follow‐up was sig‐
nificantly lower in DILI patients (15.0% vs 70.0%, P < .01).
4  | DISCUSSION
Autoimmune features in patients with DILI11 or seronegative AIH8 
may pose significant difficulties in finding the right diagnosis and 
thus treatment. In those cases, the most reliable criterion to dis‐
tinguish DILI with autoimmune features from idiopathic AIH is the 
absence of relapse at least 1 year after disease onset when immu‐
nosuppressive therapy has been reduced, discontinued or was never 
initiated.7,11,18 However, once corticosteroids have been initiated, it 
is not known when and how to taper immunosuppression if DILI is 
suspected since no discriminating feature other than a more ben‐
eficial outcome in DILI patients under long‐term immunosuppres‐
sion has been described as yet. Therefore, despite AIH score and 
RUCAM, diagnostic criteria to discriminate DILI and AIH early after 
starting immunosuppression are urgently needed in to avoid unnec‐
essary long‐term immunosuppressive treatment in DILI patients.
On this background, we compared 44 patients with the final di‐
agnosis of AIH or DILI who were treated with corticosteroids. In our 
cohort, elevation of liver tests at the onset of disease and the pro‐
portion of patients developing ALF were fairly similar. The majority 
of patients (77.3% of patients with DILI and 86.4% of patients with 
AIH) was positive for ANA. Some patients in each group also tested 
positive for other autoantibodies associated with AIH. This finding 
is consistent with previous studies reporting that not only patients 
with AIH but also a proportion of DILI patients present with auto‐
antibodies.35,36 Therefore, the presence of autoantibodies was not 
helpful to distinguish both entities.
Interestingly, polymorphism of HLA‐DR3 or ‐DR4 was equally 
prevalent in DILI and AIH patients (70% vs 67%). HLA‐DRB1*03:01 
and HL‐DRB1*04:01 encoding HLA‐DR3 and HLA‐DR4 are alleles 
with a well‐known association to a higher susceptibility for AIH type 
1 in Europe and North America.37,38 Regarding DILI, a variety of asso‐
ciations with HLA variants have been described, that is, HLA‐B*57:01 
in the case of flucloxacillin‐induced DILI, HLA‐DRB1*15:01 in the 
case of DILI induced by amoxicillin/clavulanic acid and HLA‐A*33:01 
for a variety of drugs including ticlopidine, methyldopa erythromy‐
cin and fenofibrates.39‐42 However, no association of HLA‐DR3 and 
‐DR4 with DILI has been described so far, although previous data 
have shown that a proportion of DILI patients and healthy controls 
can present with those HLA variants albeit less frequently than in 
AIH patients.43,44 Our data suggest that HLA variants associated 
with higher susceptibility for AIH might also be present in a relevant 
proportion of DILI patients. However, towing to the limited number 
of patients for which HLA genotyping was available no statistically 
significant results can be concluded from the present data.
In our cohort, the pretreatment AIH score was significantly 
higher in AIH patients, whereas RUCAM was significantly higher 
in DILI patients. However, the sensitivity and specificity of the pre‐
treatment AIH score with a cut‐off of ≥12 were only 59% and 82% 
respectively. The sensitivity and specificity of the pretreatment AIH 
score were even lower for the simplified AIH score, most likely be‐
cause of the observation that a high proportion of AIH patients in 
our cohort were seronegative and presented with a histology only 
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compatible but not typical for AIH. The sensitivity and specificity 
of the RUCAM were 32% and 91% respectively. Histological anal‐
ysis of liver biopsies could not distinguish DILI and AIH either since 
the only significant difference was the predominance of interface 
infiltrates in AIH patients. In addition, there was a tendency, albeit 
not significant, towards a higher frequency of eosinophils in AIH 
patients. Both of those findings are in line with previous data.14,45 
However, regarding the type and intensity of cellular infiltrates and 
of cholestasis no other distinguishing feature was found that could 
have helped to accurately direct diagnosis towards DILI or AIH.
These findings confirm the need for methods to improve dis‐
crimination of AIH and DILI, especially if corticosteroid treatment 
has been initiated in inconclusive cases. However, data on the short‐
term outcome of DILI patients under immunosuppressive treatment 
and optimal tapering regimes are scarce.
Strikingly, we observed marked differences in the response to 
only 1 week of corticosteroid treatment between patients with AIH 
and DILI. The absolute and relative reductions in serum ALT levels 
per day during the first week of treatment were significantly higher 
in the DILI group than in patients with AIH.
Notably, for a cut‐off value of 9% reduction in ALT levels 
per day during the first week of treatment, the sensitivity and 
specificity reached 77% respectively. Thus, decrease in ALT lev‐
els seems to be a useful tool to support the pretreatment AIH 
score and RUCAM, especially in complex cases: The reduction 
in ALT per day during the first week of corticosteroid treatment 
showed excellent results when differentiating DILI and AIH pa‐
tients who had been misclassified by the RUCAM or AIH score 
with a sensitivity and specificity of both 100%. In addition, the 
relative ALT reduction in patients with an inconclusive score re‐
sult (both RUCAM and AIH scores being either ≥6 and ≥12 or <6 
and <12) exhibited a sensitivity and specificity of 78% and 75% 
respectively. In all patients, who were either misclassified or in‐
conclusive at treatment initiation, a 9% reduction in ALT levels 
per day during the first week of treatment discriminated DILI from 
AIH with 83% sensitivity and specificity respectively. However, 
not only in complex, initially inconclusive cases, but also in the 
unequivocal cases in our cohort (n = 24), the relative reduction in 
ALT could distinguish between DILI and AIH with a sensitivity and 
specificity of 88% and 75% respectively.
This supports our findings for the total cohort comprising 
both unequivocal and inconclusive cases. In addition to the con‐
ventional causality assessment and histological evaluation, an in 
vitro test established in our centre was applied to all patients of 
the current study. This in‐house test is based on drug reactivity 
of hepatocyte‐like cells generated from monocytes of individual 
subjects for the diagnosis or exclusion of DILI.24,25 Interestingly, 
the MH cell test identified the culprit drug or a combination of 
drugs in all DILI patients, while the test was negative for all drugs 
used by AIH patients. Thus, supporting the final diagnosis used 
for our analysis.
To the best of our knowledge, this study is the first to show 
a significant difference in the response of laboratory parameters 
to short‐term corticosteroid therapy between patients with DILI 
and AIH, enabling the differentiation of the two entities early in 
the course of immunosuppressive therapy. Based on these find‐
ings, the dynamics of ALT levels in patients undergoing cortico‐
steroid therapy recorded shortly after initiation are a potentially 
useful additional diagnostic criterion to distinguish DILI patients 
who have been initiated on corticosteroids because of the pres‐
ence of autoimmune features or persistency of liver injury from 
idiopathic AIH. Notably, the median times to ALT normalization 
were not different between AIH and DILI patients in our cohort. 
This observation underscores our finding of the particular im‐
portance of the difference in Delta ALT during the first week of 
treatment.
We propose that a reduction in ALT levels of 9% per day during 
the first week of steroid treatment indicates that the patient is suf‐
fering from a DILI episode rather than idiopathic AIH and the risk of 
relapse upon tapering and withdrawal of immunosuppression might 
be minimal. The reduction of ALT should especially be regarded in 
patients in whom the diagnosis of DILI or AIH is inconclusive with 
the RUCAM and AIH score.
Our study has limitations, such as the rather small number of pa‐
tients. Secondly, all of the patients included were Caucasian. Thus, 
there is a potential selection bias of milder DILI cases, since recent data 
suggest that African‐Americans are more likely to develop a more se‐
vere form of DILI with higher morbidity and mortality.46 Furthermore, 
the analysis was conducted in a highly selected cohort comprising pa‐
tients with intake of at least one drug who received corticosteroids 
during the course of their disease. In addition, the analysis could only 
be done retrospectively, since a response to immunosuppressive ther‐
apy and the appearance of relapse must be considered as an additional 
diagnostic criterion. In conclusion, the dynamics of ALT levels shortly 
after the initiation of immunosuppressive therapy seems to represents 
a useful diagnostic tool to help separate DILI from AIH.
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